Introduction
The TERC gene is vital for maintaining telomeres, and reduced TERC levels can lead to shortened telomeres, which are linked to diseases like aplastic anemia and congenital keratosis.
Cell reprogramming can reverse cell differentiation, turning them into powerful stem cells with extended telomeres. This study explores how reprogramming affects telomere length and its connection to aplastic anemia, with the goal of finding new diagnostic tools and treatments for AA patients.
Effects of TERC on telomere length
Telomeres are protective caps at the ends of chromosomes, crucial for maintaining genomic integrity during cell division. Over time, they can shorten, leading to telomere-related diseases like aplastic anemia (AA).
Telomerase, a nucleoprotein reverse transcriptase, plays a vital role in regulating telomere length. It consists of TERC and other proteins that restore and lengthen telomeres during DNA replication.
Telomerase is crucial for maintaining genomic stability and cell viability and is implicated in cancer progression.
Telomerase activity is tightly controlled in different cell types. In most cells, its activity decreases as they mature, contributing to cellular senescence and death. However, in many cancers, telomerase is reactivated, promoting malignant transformation.
TERC, the RNA component of telomerase, is vital for catalytic activity and maintaining genomic stability. It provides a template for telomere DNA synthesis, potentially offering insights into diagnosing and treating telomere-related diseases like AA.
Effect of TERC haploinsufficiency on hematopoietic function in AA
Telomeres naturally shorten to inhibit continuous cell division, but very short telomeres can lead to fusion and genomic instability, which is associated with acquired aplastic anemia (AA).
Telomere dysfunction can result in excessive shortening and bone marrow failure, a common feature of AA.
Studies have shown that severe AA patients have shortened telomeres in their cells, indicating increased stress in the bone marrow and hematopoietic deficiency. This contributes to the development of AA.
In AA patients, T lymphocytes exhibit abnormal marker expression and shorter telomeres, suggesting a link between telomere shortening and T cell hyperfunction, potentially explaining the disease’s pathogenesis.
The telomerase RNA component (TERC) can regulate myeloid gene expression and promote myeloid response.
Enhancing TERC activity can increase telomerase activity, improve hematopoietic cell function, and maintain hematopoietic stem cell homeostasis.
However, maintaining TERC activity can be challenging, and sustaining telomerase levels during multidirectional differentiation remains a limitation.
Cell reprogramming alleviates AA hematopoietic failure
Cell reprogramming is a therapeutic approach that can modify cell behavior, induce gene expression changes, and transform cells into different types, enhancing their stem cell-like properties.
This process offers the potential for cellular regeneration. In cases of telomere-related gene mutations and haploinsufficiency, reprogramming mature cells can boost TERC activity and extend telomere length, potentially benefiting patients with aplastic anemia (AA).
Cell reprogramming can alter cell fate through transcription factors and non-coding RNA, making somatic cells more proliferative and versatile than primary cells.
There are two types of cell reprogramming: direct and indirect. Direct reprogramming is more efficient and suitable for in vivo tissue repair, while indirect reprogramming can generate target cells in large quantities for ex vivo production.
Direct reprogramming retains the origin cells’ epigenetic features, including aging-related characteristics. Aplastic anemia often results from defects in hematopoietic stem cells (HSCs), leading to insufficient blood cell production.
HSC transplantation is a common treatment, but it has complications. Cell reprogramming may offer an alternative approach by increasing telomere length and improving bone marrow hematopoiesis, potentially reversing hematopoietic failure in AA patients.
Clinical strategies for improving TERC function via cell reprogramming in the treatment of AA
Telomere haploinsufficiency can disrupt gene expression, leading to genomic instability, cell cycle arrest, bone marrow failure, reduced TERC activity, accelerated telomere shortening, and decreased hematopoietic stem cell (HSC) count, ultimately contributing to aplastic anemia (AA) progression.
Cell reprogramming offers hope for overcoming these issues.
It can transform mature cells into more versatile stem cells with improved TERC function, longer telomeres, and enhanced HSCs, potentially alleviating bone marrow hematopoietic failure in AA patients.
Treatment of AA via MSC cell reprogramming
Mesenchymal stem cells (MSCs) have therapeutic potential in AA treatment. They can restore a healthy hematopoietic microenvironment and promote bone marrow hematopoiesis, making them crucial for AA recovery when combined with HSC transplantation.
However, current clinical MSCs have limitations, including low purity and cell senescence.
To address these issues, researchers are turning to cell reprogramming to generate a large quantity of high-quality MSCs, with embryonic stem cells being a valuable source.
These reprogrammed MSCs possess advantages in proliferation, differentiation, and immune modulation, making them promising in the field of regenerative medicine.
MSCs in the bone marrow play a key role in cell reprogramming, promoting hematopoietic function and restoring the bone marrow microenvironment.
Research on the use of MSC cell reprogramming for AA treatment is limited but holds promise for developing novel therapeutic strategies.
Treatment of AA via iPSC cell reprogramming
Embryonic stem cells (ESCs) exhibit high telomerase levels, which help maintain telomeres, pluripotency, and diverse differentiation. But ESCs have immune rejection issues and ethical concerns, making induced pluripotent stem cells (iPSCs) an important choice for regenerative therapy.
iPSCs, created through reprogramming, don’t provoke immune responses when transplanted. However, their efficiency can be affected by various factors like culture conditions and gene expression.
Studies confirm iPSCs’ therapeutic potential for heart, eye, and neurological diseases. Telomere haploinsufficiency, which affects TERC activity and telomere length, can be addressed using iPSCs. They can upregulate TERC expression, extend telomeres, and protect hematopoietic differentiation.
Cell reprogramming is a valuable tool for studying telomere dynamics and reversing telomere-related diseases, but further validation is needed for clinical use.
Researchers are actively exploring iPSCs in this context, with promising results for improving telomere depletion in diseases like AA.
Direct reprogramming can overcome some technical challenges of iPSCs, making it a valuable strategy for regenerative therapeutics. This advancement holds potential for the diagnosis and treatment of AA and other diseases.
Conclusions
Telomerase activity disorders, often linked to TERC gene haploinsufficiency, play a significant role in telomere-related diseases like aplastic anemia (AA).
TERC maintains telomere length, and its deficiency can lead to telomere shortening, DNA damage, and various diseases. Correcting TERC haploinsufficiency offers a promising avenue for treating such conditions.
Cell reprogramming, a method for altering cell types, can address TERC haploinsufficiency by extending telomeres and enhancing telomerase activity.
It has the potential to reverse telomere loss in AA patients and maintain epigenetic transcriptional regulation. However, choosing the right reprogramming pathway based on cell characteristics and the disease’s nature is crucial.
Cells with strong differentiation abilities, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), can be targeted for cell reprogramming. They protect telomerase activity, maintain telomere length, and reduce telomere depletion-related diseases. Reprogramming somatic cells into pluripotent stem cells offers a viable alternative to embryonic stem cells, bypassing ethical concerns. While the application of cell reprogramming in AA is an emerging field with limited research, it holds great potential to reduce AA associated with telomere loss and opens new possibilities for clinical treatment. This review offers insights that could shape AA-targeted therapeutics.
References
1. Aalbers AM, et al. Human telomere disease due to disruption of the CCAAT box of the TERC promoter. Blood. 2012;119(13):3060–3. Article CAS PubMed PubMed Central Google Scholar
2. Abbar AA, et al. Induced pluripotent stem cells: reprogramming platforms and applications in cell replacement therapy. BioRes Open Access. 2020;9:121–36. Article PubMed PubMed Central Google Scholar
3. Argaez-Sosa AA, et al. Higher expression of DNA (de)methylation-related genes reduces adipogenicity in dental pulp stem cells. Front Cell Dev Biol. 2022;10: 791667. Article PubMed PubMed Central Google Scholar
4. Bazina F, et al. Reprogramming oral epithelial keratinocytes into a pluripotent phenotype for tissue regeneration. Clin Exp Dent Res. 2021;7:1112–21. Article PubMed PubMed Central Google Scholar
5. Blau HM, Daley GQ. Stem cells in the treatment of disease. N Engl J Med. 2019;380:1748–60. Article CAS PubMed Google Scholar
6. Bloom SI, et al. Aging results in DNA damage and telomere dysfunction that is greater in endothelial versus vascular smooth muscle cells and is exacerbated in atheroprone regions. Geroscience. 2022;44:2741–55.
Article CAS PubMed PubMed Central Google Scholar
7. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009a;361(24):2353–65. Article CAS PubMed PubMed Central Google Scholar
8. Carvalho VS, et al. Recent advances in understanding telomere diseases. Fac Rev. 2022;11:31. Article CAS PubMed PubMed Central Google Scholar
9. Costoya JA, Arce VM. Cancer cells escape the immune system by increasing stemness through epigenetic reprogramming. Cell Mol Immunol. 2022;20:6–7. Article PubMed Google Scholar
10. Davies JE, et al. Concise review: Wharton’s jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Transl Med. 2017;6:1620–30. Article PubMed PubMed Central Google Scholar
11. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A. 2003;100:3547–9. Article CAS PubMed PubMed Central Google Scholar
12. Ding P, et al. Osteocytes regulate senescence of bone and bone marrow. Elife. 2022;11: e81480. Article PubMed PubMed Central Google Scholar
13. Fujii S, et al. Graft-versus-host disease amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naive T cell populations. Stem Cells. 2018;36:434–45.
Article CAS PubMed Google Scholar
14. Gajbhiye SS, et al. Clinical and etiological profiles of patients with pancytopenia in a tertiary care hospital. Cureus. 2022;14: e30449. PubMed PubMed Central Google Scholar
15. García-Castillo J, et al. Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Proc Natl Acad Sci USA. 2021;118: e2015528118. Article PubMed PubMed Central Google Scholar
16. Gascón S, et al. Direct neuronal reprogramming: achievements, hurdles, and new roads to success. Cell Stem Cell. 2017;21:18–34. Article PubMed Google Scholar
17. Glousker G, Lingner J. TFIIH moonlighting at telomeres. Genes Dev. 2022;36:951–3. CAS PubMed PubMed Central Google Scholar
